Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) closed at $180.05 in the last session, down -0.47% from day before closing price of $180.9. In other words, the price has decreased by -$0.47 from its previous closing price. On the day, 1.12 million shares were traded. JAZZ stock price reached its highest trading level at $182.75 during the session, while it also had its lowest trading level at $178.01.
Ratios:
We take a closer look at JAZZ’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.35 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.19. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.11.
On July 15, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $152. UBS Upgraded its Neutral to Buy on March 07, 2025, whereas the target price for the stock was revised from $145 to $179.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 20 ’25 when McSharry Heather Ann sold 3,415 shares for $177.78 per share. The transaction valued at 607,127 led to the insider holds 20,449 shares of the business.
COZADD BRUCE C sold 18,000 shares of JAZZ for $3,259,538 on Nov 18 ’25. The Director now owns 390,826 shares after completing the transaction at $181.09 per share. On Nov 18 ’25, another insider, Carr Patricia, who serves as the SVP, Chief Accounting Officer of the company, sold 5,319 shares for $182.06 each. As a result, the insider received 968,402 and left with 7,012 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 10940759040 and an Enterprise Value of 14323649536. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.63 while its Price-to-Book (P/B) ratio in mrq is 2.76. Its current Enterprise Value per Revenue stands at 3.445 whereas that against EBITDA is 8.908.
Stock Price History:
The Beta on a monthly basis for JAZZ is 0.24, which has changed by 0.4750489 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, JAZZ has reached a high of $182.99, while it has fallen to a 52-week low of $95.49. The 50-Day Moving Average of the stock is 27.66%, while the 200-Day Moving Average is calculated to be 45.11%.
Shares Statistics:
According to the various share statistics, JAZZ traded on average about 941.52K shares per day over the past 3-months and 2172440 shares per day over the past 10 days. A total of 60.74M shares are outstanding, with a floating share count of 57.99M. Insiders hold about 4.60% of the company’s shares, while institutions hold 98.81% stake in the company. Shares short for JAZZ as of 1763078400 were 4839654 with a Short Ratio of 5.43, compared to 1760486400 on 4689812. Therefore, it implies a Short% of Shares Outstanding of 4839654 and a Short% of Float of 9.2.
Earnings Estimates
. The current rating of Jazz Pharmaceuticals plc (JAZZ) is the result of assessments by 16.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $4.44, with high estimates of $5.96 and low estimates of $3.52.
Analysts are recommending an EPS of between $8.82 and $7.71 for the fiscal current year, implying an average EPS of $8.11. EPS for the following year is $22.71, with 16.0 analysts recommending between $30.05 and $19.92.
Revenue Estimates
According to 15 analysts, . The current quarter’s revenue is expected to be $1.16B. It ranges from a high estimate of $1.22B to a low estimate of $1.11B. As of . The current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $1.09BFor the next quarter, 15 analysts are estimating revenue of $977.05M. There is a high estimate of $1.1B for the next quarter, whereas the lowest estimate is $903.7M.
A total of 17 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.29B, while the lowest revenue estimate was $4.18B, resulting in an average revenue estimate of $4.23B. In the same quarter a year ago, actual revenue was $4.07BBased on 17 analysts’ estimates, the company’s revenue will be $4.52B in the next fiscal year. The high estimate is $4.98B and the low estimate is $4.12B.
